Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre

Background: Metastatic renal cell carcinoma is chemoresistant and radioresistant disease with poor survival historically, but outcome has improved in past decade after introduction of tyrosine kinase inhibitors like sunitinib and sorafenib. Sorafenib has not been tested in Indian patients with metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Saxena, Mohith, Madabhavi, Irappa, Patel, Apurva, Panchal, Harsha, Anand, Asha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305272/
https://www.ncbi.nlm.nih.gov/pubmed/30595822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305272/
https://www.ncbi.nlm.nih.gov/pubmed/30595822

Ejemplares similares